Top Markets
#1 Zora Zora +31.68%
#2 AI XOVIA AI XOVIA +30.82%
#3 Full Moon Full Moon +18.72%
#4 0G 0G +17.40%
#5 Notcoin Notcoin +16.40%
#6 Wrapped NXM Wrapped NXM +11.91%
#7 rsERG rsERG +11.83%
#8 Seeker Seeker +10.75%
#9 Axelar Axelar +10.62%
#10 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +10.43%
Coin of the day
Zora Zora
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Autolus Therapeutics plc Autolus Therapeutics plc

Autolus Therapeutics plc

AUTL
Classifica tra le azioni #12080
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily... Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
Prezzo delle azioni
$2.34
Ultima sincronizzazione: 2026-08-28
Capitalizzazione di mercato
$621.44M
Variazione (1 giorno)
-1.06%
Variazione (1 anno)
55.67%
Paese
GB
Scambia Autolus Therapeutics plc (AUTL)

Categoria

Healthcare
Utile per Autolus Therapeutics plc (AUTL)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Autolus Therapeutics plc, gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Autolus Therapeutics plc dal 2026 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
Non abbastanza dati per le date fornite.
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH